Skip to main content

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

The Original Article was published on 08 October 2020

Correction to: J Hematol Oncol (2020) 13:132

The original article [18] mistakenly contains duplicate references. The correct reference list can be viewed in this Correction article.


  1. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.

    Article  CAS  Google Scholar 

  2. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia. 2012;26(10):2176–85.

    Article  CAS  Google Scholar 

  3. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64.

    Article  CAS  Google Scholar 

  4. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061–75.

    Article  CAS  Google Scholar 

  5. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40.

    Article  CAS  Google Scholar 

  6. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–97.

    Article  CAS  Google Scholar 

  7. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J ClinOncol. 2013;31(29):3681–7.

    Article  CAS  Google Scholar 

  8. Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903.

    Article  CAS  Google Scholar 

  9. Levis MJ, Smith CC, Ishizuka K, Kobayashi K, Arunachalam M, Wang Y, Lazzaretto D, Cortes JE. Post hoc exploratory analysis of two phase 2 trials of quizartinibmonotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. J ClinOncol. 2018;36:7017.

    Article  Google Scholar 

  10. Perl AE. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. In: Proceedings of the 110th annual meeting of the American Association for Cancer Research; Atlanta, GA.: AACR; 2019.

  11. Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, et al. Phase 2b study of 2 dosing regimens of quizartinibmonotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132(6):598–607.

    Article  CAS  Google Scholar 

  12. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J ClinOncol. 2003;21(24):4642–9.

    Article  Google Scholar 

  13. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.

    Article  Google Scholar 

  14. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–62.

    Article  CAS  Google Scholar 

  15. Rollig C, Serve H, Huttmann A, Noppeney R, Muller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–9.

    Article  Google Scholar 

  16. NCCN Clinical Practice Guidelines in AML National Comprehensive Cancer Network 2019;Version 3.

  17. Swaminathan M, Kantarjian H, Daver N, Borthakur G, Ohanian M, Kadia T, DiNardo C, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour E, Alvarado Y, Wierda W, Pinsoy MR, Ravandi F, Cortes J. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017;128:1642.

    Google Scholar 

  18. Yilmaz M, et al. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J HematolOncol. 2020;13:132.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Naval G. Daver.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yilmaz, M., Alfayez, M., DiNardo, C.D. et al. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14, 34 (2021).

Download citation

  • Published:

  • DOI: